OR11H1 and neoplasm: We were interested in comparing the tumor microenvironment between primary tumor and metastatic sites in patients who experienced development of metastatic disease.41,42 In the current study, the immunohistochemical expression score of tenascin-C or OR11H1 did not differ significantly between the primary tumor and metastatic sites.